Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vesicare | Solifenacin succinate | Bladder, overactive | Do not list | Complete | ||
Alvesco | Ciclesonide | asthma | List | Complete | ||
Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | ||
Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Azilect | Rasagiline mesylate | Parkinson's disease | Do not list | Complete | ||
Denavir | Penciclovir | Herpes labialis (cold sores) | Do not list | Complete | ||
Revatio | Sildenafil citrate | Pulmonary arterial hypertension (WHO class II and III) | List in a similar manner | Complete | ||
Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete | ||
Vantas | Histrelin acetate | Cancer, prostate | Do not list | Complete | ||
Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | N/A | Complete |